Roquefort Investments PLC Acquisition Completion, Admission & Voting Rights (2448W)
December 21 2021 - 1:59AM
UK Regulatory
TIDMROQ
RNS Number : 2448W
Roquefort Investments PLC
21 December 2021
21 December 2021
Roquefort Investments plc
("Roquefort Investments" or the "Company")
Acquisition Completion,
Admission & Voting Rights
Roquefort Investments (LSE:ROQ), the London listed investment
company established to acquire businesses focused on early-stage
opportunities in the biotechnology sector , is pleased to announce
the completion of its acquisition of the entire issued share
capital of Lyramid Pty Limited ("Lyramid") for an initial
consideration of a cash payment of GBP500,000 ("Cash
Consideration") and the issue of 5,000,000 new ordinary shares
("Consideration Shares") (the "Acquisition"). The Acquisition
constituted a reverse takeover of the Company pursuant to the
Listing Rules.
Roquefort Investments is also pleased to announce that admission
of its Enlarged Share Capital, comprising 71,900,000 ordinary
shares of GBP0.01 each, to the Official List of the UKLA by way of
a standard listing under Chapter 14 of the UKLA's Listing Rules and
to trading on the London Stock Exchange's main market for listed
securities will take place at 8:00a.m. today ("Admission").
The Company's Admission follows a successful placing, raising
gross proceeds of GBP3,000,000 via the issue of 30,000,000 Ordinary
Shares at a price of 10 pence per share (the "Placing"). The net
proceeds of the Placing, together with existing cash, are intended
to be used to fund the Cash Consideration for the Acquisition,
pre-clinical drug development and working capital.
On Admission, completion of the Acquisition becomes effective
and accordingly the Company has today paid the Cash
Consideration.
Pursuant to a special resolution passed at the Company's general
meeting held on 13 December 2021, the Company resolved to change
its name to Roquefort Therapeutics plc subject to Admission. The
Company will lodge the relevant documents with Companies House to
effect the change of name which will become effective once
confirmed by Companies House. A further announcement will be made
when the change of name becomes effective. Following the change of
name, the Company's ordinary shares will continue to trade under
the ticker ROQ, ISIN GB00BMDQ2T15 and SEDOL code BMDQ2T1.
The Company confirms that with effect from Admission, the
Company will have 71,900,000 ordinary shares of GBP0.01 each, with
each share carrying the right to one vote. The Company does not
hold any ordinary shares in treasury. The figure of 71,900,000 may
be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or of a change to their interest in the Company under
the FCA's Disclosure and Transparency Rules .
Capitalised terms used in this announcement (unless otherwise
defined) carry the same meanings as those ascribed to them in the
Company's Prospectus dated 16 December 2021, unless the context
requires otherwise.
The Prospectus and further information on the Company can be
found on Roquefort Investment's website at:
www.roquefortinvest.com
Stephen West, Executive Chairman, commented:
"Today is an important milestone for Roquefort Investments as we
complete our acquisition of Lyramid and recommence trading on the
LSE. I would like to thank the team at Lyramid for their hard work
and dedication to help make this transformational transaction
happen.
"The reception we have received from investors has been
extremely positive and we are very excited to be embarking on the
next of phase of our growth story as we continue Lyramid's
development of Midkine inhibiting RNA therapeutic drugs targeting a
number of diseases settings."
Enquiries:
Roquefort Investments plc
+44 (0)20 3290
Stephen West (Chairman) 9339
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George +44 (0)20 7466
Beale 5000
roq@buchanan.uk.com
Optiva Securities Limited (Broker)
+44 (0)20 3411
Christian Dennis 1881
For further information, please visit www.roquefortinvest.com
and @roquefortinvest on Twitter.
LEI: 254900P4SISIWOR9RH34
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation (EU) No 596/2014 as it
forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018, as amended ("MAR"). Upon the publication of
this announcement via Regulatory Information Service, this inside
information is now considered to be in the public domain.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RENEASAEAEFFFFA
(END) Dow Jones Newswires
December 21, 2021 01:59 ET (06:59 GMT)
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jul 2023 to Jul 2024